Generation of an antibody directed against secreted Sema3E might be a promising approach, but considering the huge population of patients with unhealthy obesity and/or diabetes, we considered it crucial to develop a therapy that was also reasonable in terms of medical economy. This evidence concerns the gene SEMA3E and diabetes mellitus.